S
Shu Li
Researcher at Janssen Pharmaceutica
Publications - 80
Citations - 10917
Shu Li is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Psoriasis Area and Severity Index & Ustekinumab. The author has an hindex of 32, co-authored 77 publications receiving 9532 citations. Previous affiliations of Shu Li include Johnson & Johnson Pharmaceutical Research and Development & University of Medicine and Dentistry of New Jersey.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi,Alexa B. Kimball,Kim A. Papp,Newman Yeilding,Cynthia Guzzo,Y. Wang,Shu Li,Lisa T. Dooley,Kenneth B. Gordon +8 more
TL;DR: Ustekinumab seems to be efficacious for the treatment of moderate-to-severe psoriasis; dosing every 12 weeks maintains efficacy for at least a year in most patients.
Journal ArticleDOI
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis : a phase III, multicentre, double-blind trial
Kristian Reich,Frank O. Nestle,Kim A. Papp,Jean-Paul Ortonne,Robert Evans,Cynthia Guzzo,Shu Li,Lisa T. Dooley,Christopher E.M. Griffiths +8 more
TL;DR: Infliximab is effective in both an induction and maintenance regimen for the treatment of moderate-to-severe psoriasis, with a high percentage of patients achieving sustained PASI 75 and PASi 90 improvement through 1 year.
Journal ArticleDOI
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E.M. Griffiths,Bruce Strober,Peter C.M. van de Kerkhof,Vincent T. Ho,Roseanne Fidelus-Gort,Newman Yeilding,Cynthia Guzzo,Yichuan Xia,B. Zhou,Shu Li,Lisa T. Dooley,Neil H. Goldstein,Alan Menter +12 more
TL;DR: The efficacy of ustekinumab at a dose of 45 or 90 mg was superior to that of high-dose etanercept over a 12-week period in patients with psoriasis.
Journal ArticleDOI
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes,Arthur Kavanaugh,Alice B. Gottlieb,Lluís Puig,Proton Rahman,Christopher T. Ritchlin,Carrie Brodmerkel,Shu Li,Y. Wang,Alan M. Mendelsohn,Mittie K. Doyle +10 more
TL;DR: Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments.
Journal ArticleDOI
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
Andrew Blauvelt,Kim A. Papp,Christopher E.M. Griffiths,Bruce Randazzo,Bruce Randazzo,Y. Wasfi,Yaung-Kaung Shen,Shu Li,Alexa B. Kimball +8 more
TL;DR: Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1 year and significantly improved patient‐reported outcomes through week 48.